There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Plus Therapeutics (PSTV – Research Report) and Milestone Pharmaceuticals (MIST – Research Report) with bullish sentiments.
Milestone Pharmaceuticals (MIST)
H.C. Wainwright analyst Patrick Trucchio reiterated a Buy rating on Milestone Pharmaceuticals today and set a price target of $25.00. The company’s shares closed last Friday at $1.65, close to its 52-week low of $1.33.
According to TipRanks.com, Trucchio ‘s ranking currently consits of 0 on a 0-5 ranking scale, with an average return of
The word on The Street in general, suggests a Strong Buy analyst consensus rating for Milestone Pharmaceuticals with a $13.00 average price target, implying a 733.3% upside from current levels. In a report released today, TD Cowen also assigned a Buy rating to the stock with a $9.00 price target.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Read More on PSTV:
- Plus Therapeutics CEO’s Insightful Presentation Now Available
- Plus Therapeutics completes dosing in Cohort 5 of ReSPECT-LM Phase 1 trial
- Plus Therapeutics Is Worried About This – Should You Be Worried Too?
- Plus Therapeutics reports FY23 EPS ($4.24) vs ($11.58) last year
- Plus Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Business Highlights
